《Nature,1月28日,SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity》

  • 来源专题:COVID-19科研动态监测
  • 编译者: zhangmin
  • 发布时间:2021-02-22
  • SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity

    Benjamin Trinité, Ferran Tarrés-Freixas, […]Julià Blanco

    Scientific Reports volume 11, Article number: 2608 (2021)

    Abstract

    The protective effect of neutralizing antibodies in SARS-CoV-2 infected individuals is not yet well defined. To address this issue, we have analyzed the kinetics of neutralizing antibody responses and their association with disease severity. Between March and May 2020, the prospective KING study enrolled 72 COVID-19+ participants grouped according to disease severity. SARS-CoV-2 infection was diagnosed by serological and virological tests. Plasma neutralizing responses were assessed against replicative virus and pseudoviral particles. Multiple regression and non-parametric tests were used to analyze dependence of parameters. The magnitude of neutralizing titers significantly increased with disease severity. Hospitalized individuals developed higher titers compared to mild-symptomatic and asymptomatic individuals, which together showed titers below the detection limit in 50% of cases. Longitudinal analysis confirmed the strong differences in neutralizing titers between non-hospitalized and hospitalized participants and showed rapid kinetics of appearance of neutralizing antibodies (50% and 80% of maximal activity reached after 11 and 17 days after symptoms onset, respectively) in hospitalized patients. No significant impact of age, gender or treatment on the neutralizing titers was observed in this limited cohort. These data identify a clear association of humoral immunity with disease severity and point to immune mechanisms other than antibodies as relevant players in COVID-19 protection.

  • 原文来源:https://www.nature.com/articles/s41598-021-81862-9
相关报告
  • 《Nature,1月29日,SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2021-02-22
    • SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus Mikail Dogan, Lina Kozhaya, Lindsey Placek, Courtney Gunter, Mesut Yigit, Rachel Hardy, Matthew Plassmeyer, Paige Coatney, Kimberleigh Lillard, Zaheer Bukhari, Michael Kleinberg, Chelsea Hayes, Moshe Arditi, Ellen Klapper, Noah Merin, Bruce Tsan-Tang Liang, Raavi Gupta, Oral Alpan & Derya Unutmaz Communications Biology volume 4, Article number: 129 (2021) Abstract Development of antibody protection during SARS-CoV-2 infection is a pressing question for public health and for vaccine development. We developed highly sensitive SARS-CoV-2-specific antibody and neutralization assays. SARS-CoV-2 Spike protein or Nucleocapsid protein specific IgG antibodies at titers more than 1:100,000 were detectable in all PCR+ subjects (n = 115) and were absent in the negative controls. Other isotype antibodies (IgA, IgG1-4) were also detected. SARS-CoV-2 neutralization was determined in COVID-19 and convalescent plasma at up to 10,000-fold dilution, using Spike protein pseudotyped lentiviruses, which were also blocked by neutralizing antibodies (NAbs). Hospitalized patients had up to 3000-fold higher antibody and neutralization titers compared to outpatients or convalescent plasma donors. Interestingly, some COVID-19 patients also possessed NAbs against SARS-CoV Spike protein pseudovirus. Together these results demonstrate the high specificity and sensitivity of our assays, which may impact understanding the quality or duration of the antibody response during COVID-19 and in determining the effectiveness of potential vaccines.
  • 《Nature,5月4日,A human monoclonal antibody blocking SARS-CoV-2 infection》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-05-05
    • A human monoclonal antibody blocking SARS-CoV-2 infection Chunyan Wang, Wentao Li, Dubravka Drabek, Nisreen M. A. Okba, Rien van Haperen, Albert D. M. E. Osterhaus, Frank J. M. van Kuppeveld, Bart L. Haagmans, Frank Grosveld & Berend-Jan Bosch Nature Communications volume 11, Article number: 2251 (2020) Abstract The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted therapeutics for treatment of this disease are currently lacking. Here we report a human monoclonal antibody that neutralizes SARS-CoV-2 (and SARS-CoV) in cell culture. This cross-neutralizing antibody targets a communal epitope on these viruses and may offer potential for prevention and treatment of COVID-19.